On Nov. 12, President Biden announced that he will nominate Robert M. Califf, MD for commissioner of the U.S. Food and Drug Administration (FDA). Califf is an internationally recognized expert in clinical trial research, health disparities, health care quality and cardiovascular medicine. He has nearly four decades of experience as a doctor, researcher, leader and public servant, including previous service as FDA Commissioner from 2016-2017. Currently, Califf is a professor of medicine at the Duke University School of Medicine, where he previously served as vice chancellor and founded the Duke Clinical Research Institute, and also works as head of clinical policy at Verily Life Sciences, a life sciences research organization. In response, the Natural Products Association (NPA), Consumer Healthcare Products Association (CHPA), and the Council For Responsible Nutrition (CRN) released the following statements: “NPA welcomes the return of a Senate confirmed commissioner to lead the Food and Drug Administration,” said NPA President and CEO Daniel Fabricant, PhD. “If confirmed, Dr. Califf will be responsible for leading the Agency during one of the most challenging moments in history. We look forward to hearing Dr. Califf’s views on enforcing DSHEA, regulating the rapidly expanding CBD industry, and addressing the issue of adulterated [...]
The post Associations Comment on the Nomination of Robert M. Califf for FDA Commissioner appeared first on Vitamin Retailer Magazine.